Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ADIL 
Adial Pharmaceuticals Inc (ADIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: ADIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.17
1 Year Target Price $2.17
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.22% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.52M USD | Price to earnings Ratio - | 1Y Target Price 2.17 |
Price to earnings Ratio - | 1Y Target Price 2.17 | ||
Volume (30-day avg) 3 | Beta 1.11 | 52 Weeks Range 0.22 - 1.30 | Updated Date 11/29/2025 |
52 Weeks Range 0.22 - 1.30 | Updated Date 11/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.6 |
Earnings Date
Report Date 2025-11-18 | When - | Estimate -0.14 | Actual -0.08 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -79.36% | Return on Equity (TTM) -155.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2916218 | Price to Sales(TTM) - |
Enterprise Value 2916218 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.49 | Shares Outstanding 23987587 | Shares Floating 23878923 |
Shares Outstanding 23987587 | Shares Floating 23878923 | ||
Percent Insiders 2.24 | Percent Institutions 3.97 |
Upturn AI SWOT
Adial Pharmaceuticals Inc
Company Overview
History and Background
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases of addiction. Founded to address unmet medical needs in addiction treatment.
Core Business Areas
- Therapeutic Development: Adial focuses on the development of AD04, a drug candidate for treating Alcohol Use Disorder (AUD).
Leadership and Structure
Adial has a management team with experience in drug development. The organizational structure is typical of a small, clinical-stage biotech company.
Top Products and Market Share
Key Offerings
- AD04: AD04 is Adial's lead product candidate, aimed at treating Alcohol Use Disorder (AUD). It is in clinical development. No current market share or revenue as product is not yet approved. Competitors in AUD treatment include naltrexone, acamprosate, and disulfiram. The competitors are Teva Pharmaceutical Industries Ltd. (TEVA) and Alkermes plc (ALKS).
Market Dynamics
Industry Overview
The pharmaceutical industry for addiction treatment is growing, driven by increasing awareness and the need for effective therapies. There is a high failure rate in clinical trials for drugs that treat addiction.
Positioning
Adial is positioning itself in the AUD treatment market with a genetically targeted approach. Adial's advantage comes from identifying patients more likely to respond to the drug.
Total Addressable Market (TAM)
The TAM for AUD treatment is significant, with millions of people affected. Adial is aiming to capture a portion of this market with its AD04 treatment. Estimated TAM is around $50 Billion. Adial is well-positioned to tap into the market.
Upturn SWOT Analysis
Strengths
- Genetically targeted approach
- Focus on Alcohol Use Disorder
- Potential for personalized medicine
Weaknesses
- Single product pipeline (AD04)
- Reliance on clinical trial success
- Limited financial resources
Opportunities
- Positive clinical trial results for AD04
- Partnerships with larger pharmaceutical companies
- Expansion into other addiction treatments
Threats
- Clinical trial failure
- Competition from existing treatments
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- TEVA
- ALKS
Competitive Landscape
Adial is a smaller player with a focused approach. The company's success depends on the competitive advantage of its genetically targeted approach. Adial is competing with large pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to the progression of AD04 through clinical trials.
Future Projections: Future growth depends on securing regulatory approval for AD04 and potential commercialization.
Recent Initiatives: Recent initiatives include progressing AD04 through clinical trials and seeking partnerships or funding opportunities.
Summary
Adial Pharmaceuticals is a high-risk, high-reward clinical-stage biotech company with a focused pipeline on AD04. Success hinges on positive clinical trial outcomes and securing necessary funding. While the company has a focused approach, it faces strong competition and regulatory challenges. AD04 is not yet approved; therefore, the company relies heavily on external sources of funding. Securing a partnership with a larger pharmaceutical company could be a game-changer for Adial's potential success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Industry Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment in biotech companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adial Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Glen Allen, VA, United States | ||
IPO Launch date 2018-07-30 | CEO, President & Director Mr. Cary John Claiborne MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.adial.com |
Full time employees 5 | Website https://www.adial.com | ||
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.